Khondrion | News

Khondrion press releases

November 8, 2024

Khondrion and Amsterdam UMC announce to initiate Phase 2 Clinical Trial of Sonlicromanol to Combat Long-Term Post-COVID Symptoms

Khondrion, a clinical-stage biopharmaceutical company specializing in mitochondrial disease therapies,...

November 7, 2024

Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease

52-week Phase 3 trial to investigate potential of novel, brain-penetrant redox-modulator with anti-inflammatory properties, in adult patients with...

October 29, 2024

Khondrion to Present Promising Advances in Mitochondrial Disease Therapy at Bio-Europe and Investival Showcase Events

NIJMEGEN, The Netherlands – October 29, 2024: Khondrion, a pioneering clinical-stage biopharmaceutical company focused on developing transformative...

October 9, 2024

Khondrion to present at Mitocon’s 14th Mitochondrial Disease Conference

NIJMEGEN, the Netherlands – 9 October, 2024: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...

September 11, 2024

Khondrion appoints Jasper Levink as Chief Financial and Business Officer

NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting...

November 1, 2023

Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1

Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1...

our stories

November 18, 2015

Interview PharmaBoardroom

Read the interview on pharmaboardroom.com Interview: Jan Smeitink – CEO, Khondrion, The Netherlands Jan Smeitink, CEO of...

October 31, 2015

Khondrion welcomes Hans Schikan

Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch...

stay updated